15:03 22/09/2014 Concerns on Biotech Stocks- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Concerns on Biotech Stocks- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
eMarketsDaily - 18 hours ago
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) [Trend Analysis] declared that the firm is slated to present a corporate overview and update at the NewsMakers in the Biotech Industry conference on Friday, September 26, 2014, at 11:30 a.m.

22:00 21/09/2014 Belviq Sales Recover From Holiday Dip
Belviq Sales Recover From Holiday Dip
Seeking Alpha (registration) - Sep 21, 2014
Arena Pharmaceuticals' (NASDAQ:ARNA) anti-obesity pill Belviq saw a full recovery from a holiday dip in sales last week with a 15% gain this week.

15:15 19/09/2014 Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
TheStreet.com - Sep 19, 2014
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.

11:52 19/09/2014 Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5%
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5%
Zacks.com - Sep 19, 2014
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.

15:51 17/09/2014 5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Motley Fool - Sep 17, 2014
Arena Pharmaceuticals (NASDAQ: ARNA ) held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline.
Belviq And Phentermine Study Awes Some Investors - Should It? (ARNA) - Seeking Alpha (registration)

15:03 15/09/2014 Arena Down On The Back Of Weigh-Loss Drug Failure
Arena Down On The Back Of Weigh-Loss Drug Failure
Bidness ETC - Sep 15, 2014
However, Arena Pharmaceuticals Inc. (ARNA) seems to be moving in the opposite direction and has declined 31.6%. Arena has been unable to deliver on expectations of its weight-loss drug, Belviq.
FDA panel backs Novo Nordisk drug for obesity - Daily Item
FDA Backs Injection for Obesity - Drug Discovery & Development

14:10 12/09/2014 Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Motley Fool - Sep 12, 2014
Arena Pharmaceuticals (NASDAQ: ARNA ) and Orexigen's (NASDAQ: OREX ) novel anti-obesity pills are among three drugs that the FDA has approved for use alongside diet and exercise to promote weight loss.
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And Vivus's ... - Bidness ETC
New anti-obesity drug is OK'd - Nashua Telegraph

6:48 11/09/2014 Rebounding Stocks: Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), KiOr Inc ...
Rebounding Stocks: Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), KiOr Inc ...
GSPInsider - Sep 11, 2014
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) traded for as little as $3.82 today, a new 52 week low for the company. However, the company's closing price reflected an eight cent boost from the figure recorded on Sept.

14:46 09/09/2014 Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Motley Fool - Sep 9, 2014
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals (NASDAQ: ARNA ) have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech ...
Arena Pharmaceuticals - A Biotech Value Investment - Seeking Alpha (registration)
Investor's Watch List –Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Image ... - Techsonian (press release)

13:07 02/09/2014 Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary ...
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary ...
MarketWatch - Sep 2, 2014
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, -2.58% today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog - NASDAQ